AIM:NYE-AIM ImmunoTech Inc (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 2.18

Change

+0.08 (+3.81)%

Market Cap

USD 0.09B

Volume

3.38M

Average Target Price

USD 5.25 (+140.83%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has research agreement with the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd. to test its drug Ampligen as an adjuvant therapy for COVID-19, the new coronavirus infectious disease caused by SARS-CoV-2. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida. Address: 2117 SW Highway 484, Ocala, FL, United States, 34473

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

+0.35 (+0.48%)

USD167.99B 29.58 2.88
ADPT Adaptive Biotechnologies Corpo..

-2.23 (-3.29%)

USD9.26B 43.96 N/A
BHVN Biohaven Pharmaceutical Holdin..

+6.79 (+8.52%)

USD4.79B N/A N/A
ADCT ADC Therapeutics SA

+0.69 (+2.07%)

USD2.56B -99,999.99 N/A
RCUS Arcus Biosciences, Inc

-0.22 (-0.57%)

USD2.49B N/A N/A
ZYME Zymeworks Inc

-3.79 (-7.27%)

USD2.40B 300.20 N/A
MYOV Myovant Sciences Ltd

-0.15 (-0.72%)

USD1.89B N/A N/A
CVM CEL-SCI Corporation

+0.72 (+5.05%)

USD0.57B N/A N/A
PFNX Pfenex Inc

N/A

USD0.44B 268.67 63.90
RFL Rafael Holdings, Inc

-0.67 (-2.57%)

USD0.41B N/A N/A

ETFs Containing AIM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 21.79% 52% F 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.79% 52% F 93% A
Trailing 12 Months  
Capital Gain 105.66% 73% C 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 105.66% 73% C 95% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 62.80% 86% B 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 62.80% 86% B 98% A+
Risk Return Profile  
Volatility (Standard Deviation) 115.85% 21% F 2% F
Risk Adjusted Return 54.21% 75% C 68% D+
Market Capitalization 0.09B 34% F 17% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 1.35 70% C- 98% A+
Price/Book Ratio 1.42 96% A 57% F
Price / Cash Flow Ratio -9.78 55% F 91% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -31.11% 75% C 11% F
Return on Invested Capital -91.11% 50% F 2% F
Return on Assets -18.77% 68% D+ 2% F
Debt to Equity Ratio 30.29% 25% F 74% C
Technical Ratios  
Short Ratio 0.80 76% C 71% C-
Short Percent 6.47% 38% F 42% F
Beta -0.93 96% A 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.